Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective

Share this Article

Singapore Med J 2013; 54(3): 169-175; http://dx.doi.org/doi:10.11622/smedj.2013045

Chin CT, Mellstrom C, Chua TS, Matchar DB
Correspondence: Dr Chin Chee Tang, chin.chee.tang@nhcs.com.sg

ABSTRACT
Introduction Ticagrelor is a novel antiplatelet drug developed to reduce atherothrombosis. The PLATO trial compared ticagrelor and aspirin to clopidogrel and aspirin in patients with acute coronary syndromes (ACS). Ticagrelor was found to be superior in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke, without increasing major bleeding events. The current study estimates the lifetime cost-effectiveness of ticagrelor relative to generic clopidogrel from a Singapore public healthcare perspective.
Methods This study used a two-part cost-effectiveness model. The first part was a 12-month decision tree (using PLATO trial data) to estimate the rates of major cardiovascular events, healthcare costs and health-related quality of life. The second part was a Markov model estimating lifetime quality-adjusted survival and costs conditional on events during the initial 12 months. Daily drug costs applied were SGD 1.05 (generic clopidogrel) and SGD 6.00 (ticagrelor). Cost per quality-adjusted life years (QALY) was estimated from a Singapore public healthcare perspective using life tables and short-term costs from Singapore, and long-term costs from South Korea. Deterministic and probabilistic sensitivity analyses were performed.
Results Ticagrelor was associated with a lifetime QALY gain of 0.13, primarily driven by lower mortality. The resulting incremental cost per QALY gained was SGD 10,136.00. Probabilistic sensitivity analysis indicated that ticagrelor had a > 99% probability of being cost-effective, given the lower recommended WHO willingness-to-pay threshold of one GDP/capita per QALY.
Conclusion Based on PLATO trial data, one-year treatment with ticagrelor versus generic clopidogrel in patients with ACS, relative to WHO reference standards, is cost-effective from a Singapore public healthcare perspective.

Keywords: acute coronary syndromes, clopidogrel, cost-effectiveness, Singapore, ticagrelor
Singapore Med J 2013; 54(3): 169-175; doi:10.11622/smedj.2013045

REFERENCES

1. National Registry of Diseases. Information paper on acute myocardial infarction in Singapore, 2007-2008. Available at: http://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/20110211AMIInform.... Accessed January 7, 2013.

2. Chan MY, Shah BR, Gao F, et al. Recalibration of the Global Registry of Acute Coronary Events risk score in a multiethnic Asian population. Am Heart J 2011; 162:291-9. http://dx.doi.org/10.1016/j.ahj.2011.05.016

3. 2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126:875-910.

4. Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120:2271-306. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192663

5. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999-3054. http://dx.doi.org/10.1093/eurheartj/ehr236

6. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33:2569-619. http://dx.doi.org/10.1093/eurheartj/ehs215

7. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27:1038-47. http://dx.doi.org/10.1093/eurheartj/ehi754

8. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157:599-605. http://dx.doi.org/10.1016/j.ahj.2009.01.003

9. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-57. http://dx.doi.org/10.1056/NEJMoa0904327 PMid:19717846

10. Nikolic E, Janzon M, Hauch O, et al. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J 2013; 34:220-8. Epub June 19, 2012. http://dx.doi.org/10.1093/eurheartj/ehs149

11. Norhammar A, Stenestrand U, Lindback J, Wallentin L. Women younger than 65 years with diabetes mellitus are a high-risk group after myocardial infarction: a report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Heart 2008; 94:1565-70. http://dx.doi.org/10.1136/hrt.2007.135038

12. Dennis MS, Burn JP, Sandercock PA, et al. Longterm survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993; 24:796-800. http://dx.doi.org/10.1161/01.STR.24.6.796

13. Olai L, Omne-Ponten M, Borgquist L, Svardsudd K. Survival, hazard function for a new event, and healthcare utilization among stroke patients over 65 years old. Stroke 2009; 40:3585-90. http://dx.doi.org/10.1161/STROKEAHA.109.556720

14. Ministry of Health, Singapore. Hospital Bill Sizes. Available at: http://www.moh.gov.sg/content/moh_web/home/costs_and_financing/HospitalB.... Accessed January 7, 2013.

15. Management Center for Health Promotion, Republic of Korea. Costeffectiveness analysis of national prevention programs for cardiovascular disease, 2007.

16. Burström K, Johannesson M, Rehnberg C. Deteriorating health status in Stockholm 1998-2002: results from repeated population surveys using the EQ-5D. Qual Life Res 2007;16:1547-53. http://dx.doi.org/10.1007/s11136-007-9243-z

17. Department of Statistics, Singapore. Complete Life Tables 2006-2011 for Singapore Resident Population. Available at: http://www.singstat.gov.sg/pubn/popn/lifetable06-11.pdf. Accessed January 7, 2013.

18.Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.

19. Sachs JD. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commision on Macroeconomics and Health. Geneva, Switzerland: World Health Organisation, 2001. Available at: http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Accessed January 7, 2013.

20. World Health Organization. Global Health Observatory Data Repository. Available at: http://apps.who.int/ghodata/?theme=country. Accessed January 7, 2013.

21. Ministry of Health, Singapore. Costs and Financing. Available at: http://www.moh.gov.sg/content/moh_web/home/costs_and_financing.html. Accessed January 7, 2013.

22. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124:544-54. http://dx.doi.org/10.1161/CIRCULATIONAHA.111.047498

23. Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105:752-9. http://dx.doi.org/10.1160/TH10-12-0807

24. Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel (editorial). Thromb Haemost 2011; 105:763-5. http://dx.doi.org/10.1160/TH11-03-0159